NAD+ Precursor Supplements vs. Senolytic Supplements for Dogs: What Each One Actually Does

By Meghan Jaskot, DVM

Comparisons · August 17, 2026 · 5 min read

NAD+ precursor supplements and senolytic supplements target aging in dogs through different mechanisms — here's which one actually fits your dog.

Start with what you’re actually trying to fix, because that decides which supplement category makes sense. If your dog is slowing down in a general, whole-body way — stiffer mornings, less enthusiasm for the stairs, a coat that’s lost some shine — you’re looking at the NAD+ precursor lane. If what worries you is more specific and cellular, especially cognitive fog or the kind of slow mental fade owners describe as their dog “just not being all there,” senolytics have the more direct evidence trail right now. They are not interchangeable, and the TikTok algorithm currently treats them like they are.

In my practice, the dog who made this distinction click for me was a nine-year-old Golden Retriever named Baxter, sixty-eight pounds, who came in because his owner noticed he’d started hesitating before getting up off the kitchen floor — not limping, just pausing, like he was doing math before committing. It had been going on for about six weeks. She’d already read three different Instagram captions calling NAD+ boosters “cellular rejuvenation” and wanted to start Baxter on one that afternoon. I asked her to walk me through what she was actually hoping would change: energy, joint comfort, or his mind. She said energy and joints. That’s a precursor conversation, not a senolytic one, and it’s the first question I ask every owner who walks in already holding a bottle.

What NAD+ Precursors Are Actually Supplying

NAD+ precursor supplements — usually nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) — give the body raw material to rebuild NAD+, a coenzyme every cell needs for energy metabolism and DNA repair, and one that measurably declines with age. The clearest human safety data comes from NR: a randomized, double-blind, placebo-controlled trial of the ingredient NIAGEN, summarized in PMC, found long-term NR administration generally well tolerated in overweight adults, with only mild side effects in a minority of participants. That’s a human trial, not a canine one — there is no equivalent long-term canine safety dataset for either NR or NMN, and dosing in dogs is extrapolated, not established. Owners should treat NAD+ precursor supplements as a support-level tool for cellular energy and general vitality, not a treatment for a diagnosed condition.

What Senolytics Are Actually Doing

Senolytics work on a completely different problem: senescent cells, the “zombie” cells that stop dividing with age but don’t die off on schedule, instead sitting around secreting inflammatory signals that drag down surrounding tissue. Compounds like quercetin and fisetin are believed to selectively push these cells toward apoptosis by blocking the anti-apoptotic proteins keeping them alive. A review in ScienceDirect lays out fisetin’s senotherapeutic mechanism and notes it outperforms quercetin in some senescent cell models, though the comparative picture between the two compounds still shifts depending on the tissue studied. This is mechanistic and early-stage science translated from rodent models into a supplement aisle faster than the evidence has fully caught up.

The One Study Everyone Cites, and What It Actually Showed

Almost every senolytic-plus-NAD+ combination product marketed for dogs points back to the same trial. A randomized, controlled clinical trial reported in Scientific Reports tested a combined senolytic and NAD+ precursor product in senior dogs and found improved owner-assessed cognitive function using a standard rating scale. That’s a genuinely notable result — it’s one of the only placebo-controlled trials of its kind in dogs. But the details matter more than the headline. SkeptVet’s review of the same data points out that the significant difference showed up at the three-month mark, without a clean dose-response relationship between the low-dose and full-dose groups, and that by six months there were no meaningful differences within or between groups at all. The specific ingredients and doses used in the study were also never fully disclosed. I take the result seriously. I don’t take it as settled.

I’ve watched this play out with an eleven-year-old terrier mix named Millie, around eighteen pounds, whose owner brought in a phone video of Millie pacing the hallway at 2 a.m. and staring at a blank wall for stretches that hadn’t happened a year earlier. The owner had seen a senolytic-NAD+ combo mentioned by three different creators in one week and wanted my read before spending on it. We talked through pill burden — Millie already took a joint chew and a thyroid tablet twice daily, and adding a third capsule mattered to an owner juggling a toddler’s schedule too. We started with the senolytic component alone, given the cognitive framing of her symptoms, and planned a recheck at eight weeks rather than assuming either ingredient would move the needle on its own.

The Counterargument, and Why I Still Land Where I Do

The honest counterargument here is that combination products exist precisely because aging isn’t one pathway — cellular energy decline and senescent cell buildup happen together, so hitting both at once is a reasonable hypothesis, not a marketing gimmick. I don’t dismiss that logic. But be honest about where the preventive evidence is thin: we have one meaningfully designed canine trial, a mixed six-month result, and an ingredient list that wasn’t disclosed. That’s not nothing, but it’s not “proven” either, no matter how many times a bottle shows up in your feed this week. I’d rather match the supplement to the specific concern a dog is showing than default to the combo because it’s trending. If cognitive change is the primary complaint, the senolytic side has the stronger — if still early — trial signal behind it. If it’s general energy and vitality, an NAD+ precursor is the more mechanistically direct pick, understanding that canine-specific dosing data isn’t there yet.

Buying quality matters as much as picking the right category — supplement form and where you buy it both affect what actually ends up in the bottle, something covered in more depth in Chew vs Powder vs Liquid Dog Supplements and Amazon vs. Brand-Direct. And if what’s really going on with your dog is joint stiffness rather than anything cellular, it’s worth ruling that out first — see Arthritis vs. Normal Aging Stiffness in Dogs before assuming a longevity supplement is the fix.

What I Actually Tell Owners

Ask what you’re trying to change before you ask which ingredient is trending. Track one or two specific, observable markers — stairs, rising time, night pacing, sleep — for at least eight weeks before deciding anything worked. Loop in your vet on dosing, especially since neither NAD+ precursors nor senolytics have established canine-specific dosing the way NIAGEN’s human trial data does. And keep some perspective: the broader canine longevity research field, including NIH-funded work like the rapamycin trial described by the AVMA, is still years from definitive answers on any single anti-aging compound in dogs.

So which one is actually worth the bottle on your counter — the one with the trending hashtag, or the one that matches what your dog is actually showing you?